Trials / Recruiting
RecruitingNCT03587844
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | brentuximab vedotin | MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg. |
| DRUG | brentuximab vedotin | LyP Brentuximab vedotin 0.9 mg/kg2 |
| DRUG | brentuximab vedotin | MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1 |
Timeline
- Start date
- 2018-07-03
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2018-07-16
- Last updated
- 2026-04-03
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03587844. Inclusion in this directory is not an endorsement.